Becton, Dickinson and (BDX) EVP Michael Feld Sells $11K of Stock

Michael Feld, Executive Vice President and Chief Revenue Officer at Becton, Dickinson and Company, sold 75 shares of the company in a planned transaction on June 26, 2026. The shares were sold at an average price of $152.8 each, totaling approximately $11,460.

Insider Buying and Selling at Becton, Dickinson and Company

In addition to Michael Feld's recent sale, several other insiders have been active. Michael David Garrison, EVP & President of Medical Essentials and BioPharma, sold 1,100 shares at $145.66 on June 24 and another 1,100 shares at $151.48 on June 10, both as planned transactions. Thomas Polen Jr., Chairman, CEO, and President, executed multiple sales on June 1, including 17,445 shares at $146.15 and 2,764 shares at $146.35, with some under planned trading arrangements.

Becton, Dickinson and Company Stock Down 13.8%

Shares of NYSE:BDX traded near $151.38 on Saturday. Becton, Dickinson has a market cap of about $41.7 billion and a P/E ratio of 26.37, with a forward P/E of 11.31. The stock has a 52-week low of $127.59 and a high of $187.35. Its 50-day moving average stands at $148.22, while the 200-day moving average is $153.98. The company's debt-to-equity ratio is 71.60, indicating a moderate level of leverage.

Analysts Set New Price Targets

On May 11, 2026, Barclays maintained its 'buy' rating on Becton, Dickinson with a price target of $204. Argus Research also maintained a 'buy' rating, setting a target of $180 on March 23, 2026. Wells Fargo and TD Cowen both maintain a 'hold' rating, with targets of $161 and $163, respectively. The overall analyst consensus suggests a 'buy' with a mean target price of $177.75 based on 12 analyst opinions.

About Becton, Dickinson and Company

Becton, Dickinson and Company, headquartered in Franklin Lakes, New Jersey, is a global leader in the medical technology sector. The company develops, manufactures, and sells a wide range of medical supplies and devices, laboratory equipment, and diagnostic products. Its products serve healthcare institutions, physicians, and researchers worldwide. Led by CEO Thomas E. Polen Jr., Becton, Dickinson employs approximately 60,000 people and operates through various segments including Medical Essentials, Connected Care, and Life Sciences.

Bottom Line

Michael Feld's planned sale of Becton, Dickinson shares is part of regular insider activity at the company. Investors keep a close eye on such transactions as they can provide insights into management's view of the company's future. However, it's important to remember that these sales are often pre-arranged and not necessarily indicative of the insider's outlook. Becton, Dickinson continues to be a significant player in the healthcare sector, with analysts maintaining a positive outlook.